articleThe LancetNov 17, 2011GREEN OA

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

MRMatthew R. SmithFSFred SaadRERobert E. ColemanNDNeal D. ShoreKFKarim Fizazi

Massachusetts General Hospital · Harvard University · +20 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

795
total citations
FWCI
44.85
Percentile
100%
References
31
Citations per year

Authors

21

Topics & keywords

Topics
Keywords
  • Denosumab
  • Medicine
  • Prostate cancer
  • Hazard ratio
  • Clinical endpoint
  • Bone metastasis
  • Internal medicine
  • Placebo
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.